Interesting update, things don't look great but that's no surprise. I thought the comments from the new CEO were good and about as critical of past management as you could really put on paper. A lot of talk about reducing spend and streamlining the business, not a lot of talk about nasal spray.
No mention of AZ as a partner outside of the about SPL blurb. It's a pity that the ASX doesn't make companies substantiate things they put in the activities report - "Starpharma’s partnered research programs, including those with MSD and Genentech, continued to progress." Wonder if they will take questions at the proposed webinar.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.29M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $12.03K | 116.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 109616 | 3 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |